COVID-19 Sterilizing Violeds Technology Succeeded in Perfect Clean Washing with Removing Odors and Sterilizing
12.5.2020 10:44:00 EEST | Business Wire | Press release
Seoul Viosys (KOSDAQ: 092190), the world’s first compound semiconductor for short wavelength solutions provider, announced that products with Violeds technology for perfectly clean laundry have been mass-produced and supplied to both Chinese two major makers, Hisense and Haier, which lead household washing machine products.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200512005367/en/
(Left) Laundry tank from below (Right) Germs found in washing machines (Graphic: Business Wire)
The level of contamination in the washing machine is approximately five times higher than in the toilet. The laundry tank, is something we can pass by without knowing, that is invisible from the outside. However, after washing, the water in the gap remains with foreign substances, which in turn causes odors, various germs and molds in the washing machine to breed.
The two companies that lead washing machine technology in China solved the problem of laundry tank sterilization and deodorization by applying Violeds technology from Seoul Viosys. With high satisfaction, it will be expanded from high-end to low-end models.
Violeds technology, which is an optical semiconductor, is new concept of clean technology developed by Seoul Viosys since 2005 with SETi in the U.S. It is the Seoul Viosys’ 4,000 patented technology brands that prevent bacteria from occurring and proliferating with photons. More than 1,000 patents for application of Violeds have been secured and verified, and the company has succeeded in extending its life span to 50,000 hours. The company has started to supply air conditioner for air purification and water sterilization products such as water supply and water purifiers.
Meanwhile, Seoul Viosys obtained results from a research center at Korea University last month that Violeds technology sterilizes the coronavirus 99.9 percent. Seoul Viosys will launch a portable personal product within this month to prevent transmission through the air and the spread of viruses on various surfaces, including facial masks and will provide temporarily with its own brand until corona situation is resolved so that it can be used to quickly save people from the pandemics of world.
Executive vice president Chae Hon Kim, who leads the UV business at Seoul Viosys, said “There have been many difficulties in developing and mass-producing ultraviolet semiconductor UV LEDs for the first time in the world. We have been working with SETi, a U.S. venture company, since 2005, and we are happy that developed as a technology even to sterilize COVID-19 to help the world.”
About Seoul Viosys
Seoul Viosys is a full-line solution provider for UV LED, VCSEL (Vertical Cavity Surface Emitting Laser), the next-generation light source for 3D sensor and laser, and a single-pixel RGB “Micro Clean Pixel” for displays. Established in 2002 as a subsidiary of Seoul Semiconductor, it captured No. 1 market share in the UV LED industry (LEDinside, 2018). Seoul Viosys has an extensive UV LED portfolio with all wavelengths range (200nm to 1600nm) including ultraviolet rays (UV), visible rays and infrared rays. It holds more than 4,000 patents related to UV LED technology. Violeds, its flagship UV LED technology, provides a wide range of industries with optimal solutions for strong sterilization and disinfection (UVC), skin regeneration (UVB), water/air purification and effective cultivation for horticulture. In 2018, Seoul Viosys acquired RayCan, a leading optoelectronic specialist, to add the advanced VCSEL technology which supports smartphone facial recognition and autonomous driving, and has started its mass production. In January 2020, it introduced a disruptive “Micro Clean Pixel” that has the potential to be a game-changer in the display market. To learn more, visit http://www.seoulviosys.com/en/.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200512005367/en/
Contact information
Media Contacts:
Seoul Semiconductor Co., Ltd.
Jeonghee Kim
Tel: +82-70-4391-8311
Email: jeonghee.kim@seoulsemicon.com
North America
Andrew Smith
Email: andrew.smith@seoulsemicon.com
Sales Contacts:
Americas
Mike Berens
mberens@s-et.com
Asia
Dong Ju Kim
djkim@seoulviosys.com
Europe
Marko Hofmann
marko.hofmann@seoulviosys.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Frasca Pilatus PC-12 PRO Flight Training Device Receives FOCA Qualification21.4.2026 17:05:00 EEST | Press release
Frasca International, Inc., a FlightSafety International company and global leader in flight simulation, today announced that its Pilatus PC-12 PRO Flight Simulation Training Device (FSTD) received Level 2 Flight Training Device (FTD2) and Flight and Navigation Procedures Trainer (FNPT II) qualification from Switzerland’s Federal Office of Civil Aviation (FOCA). Frasca is the first to develop a PC-12 PRO training device. The device equipped with Garmin’s G3000 PRIME Avionics suite is installed at Pilatus Aircraft Ltd headquarters in Stans, Switzerland, where it will support training for the next generation of PC-12 pilots. The qualification enables pilots to complete a wide range of instruments, procedural and advanced systems training in a highly immersive environment that mirrors the capabilities of the aircraft. “The PC-12 PRO leads the way with advanced features, and we’re proud to produce a state-of-the-art simulator that allows pilots to seamlessly transition from the FTD to the
Frasca Pilatus PC-12 PRO Flight Training Device Receives FOCA Qualification21.4.2026 17:05:00 EEST | Press release
Frasca International, Inc., a FlightSafety International company and global leader in flight simulation, today announced that its Pilatus PC-12 PRO Flight Simulation Training Device (FSTD) received Level 2 Flight Training Device (FTD2) and Flight and Navigation Procedures Trainer (FNPT II) qualification from Switzerland’s Federal Office of Civil Aviation (FOCA). Frasca is the first to develop a PC-12 PRO training device. The device equipped with Garmin’s G3000 PRIME Avionics suite is installed at Pilatus Aircraft Ltd headquarters in Stans, Switzerland, where it will support training for the next generation of PC-12 pilots. The qualification enables pilots to complete a wide range of instruments, procedural and advanced systems training in a highly immersive environment that mirrors the capabilities of the aircraft. “The PC-12 PRO leads the way with advanced features, and we’re proud to produce a state-of-the-art simulator that allows pilots to seamlessly transition from the FTD to the
Incyte Highlights New Phase 3 Tafasitamab Data at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting21.4.2026 17:00:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced that full results from the Phase 3 pivotal study evaluating tafasitamab (Monjuvi®/Minjuvi®) in first-line diffuse large b-cell lymphoma (DLBCL) will be featured as an oral presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, to be held May 29 – June 2, 2026, in Chicago. “The positive Phase 3 frontMIND results for tafasitamab in patients with newly diagnosed diffuse large B-cell lymphoma highlight Incyte’s continued focus on advancing novel differentiated approaches with the potential to meaningfully impact patients,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “We look forward to sharing the full data at ASCO, and to progressing our pipeline.” Presentation details: frontMIND: Phase 3 Study of tafasitamab (Tafa) Plus lenalidomide (Len) and R-CHOP for Patients (pts) with Newly Diagnosed Diffuse Large B-cell Lymphoma (DLBCL) (Abstract #7000. Session: Oral Abstract Session
Incyte Highlights New Phase 3 Tafasitamab Data at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting21.4.2026 17:00:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced that full results from the Phase 3 pivotal study evaluating tafasitamab (Monjuvi®/Minjuvi®) in first-line diffuse large b-cell lymphoma (DLBCL) will be featured as an oral presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, to be held May 29 – June 2, 2026, in Chicago. “The positive Phase 3 frontMIND results for tafasitamab in patients with newly diagnosed diffuse large B-cell lymphoma highlight Incyte’s continued focus on advancing novel differentiated approaches with the potential to meaningfully impact patients,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “We look forward to sharing the full data at ASCO, and to progressing our pipeline.” Presentation details: frontMIND: Phase 3 Study of tafasitamab (Tafa) Plus lenalidomide (Len) and R-CHOP for Patients (pts) with Newly Diagnosed Diffuse Large B-cell Lymphoma (DLBCL) (Abstract #7000. Session: Oral Abstract Session
Andersen Global Strengthens West Africa Platform with the Addition of Member Firm in Ghana21.4.2026 16:30:00 EEST | Press release
Andersen Global continues its expansion across Africa, with Lima Partners joining as a member firm and introducing the Andersen name in Ghana. Established in 2014 and headquartered in Accra, Andersen in Ghana is led by Managing Partner Daniel Addo Okoe. The firm provides a full range of professional services, including tax advisory, regulatory compliance, accounting and advisory, transfer pricing, payroll administration, immigration, and company secretarial services to both local and international clients operating in Ghana and the wider West African region. “Becoming a member firm of Andersen Global marks a significant milestone for our organization,” said Kwame Amporful, senior partner of Andersen in Ghana. “Our clients will benefit from enhanced cross-border capabilities while continuing to receive practical, high-quality advisory services tailored to the Ghanaian market.” “Ghana plays a vital role in facilitating cross-border trade and investment within West Africa,” added Mark L.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom